Gregory T J, Longmore W J, Moxley M A, Whitsett J A, Reed C R, Fowler A A, Hudson L D, Maunder R J, Crim C, Hyers T M
Medical Department, Ross Laboratories Division of Abbott Laboratories, Columbus, Ohio 43215.
J Clin Invest. 1991 Dec;88(6):1976-81. doi: 10.1172/JCI115523.
Acute Respiratory Distress Syndrome (ARDS) is characterized by lung injury and damage to the alveolar type II cells. This study sought to determine if endogenous surfactant is altered in ARDS. Bronchoalveolar lavage was performed in patients at-risk to develop ARDS (AR, n = 20), with ARDS (A, n = 66) and in normal subjects (N, n = 29). The crude surfactant pellet was analyzed for total phospholipids (PL), individual phospholipids, SP-A, SP-B, and minimum surface tension (STmin). PL was decreased in both AR and A (3.48 +/- 0.61 and 2.47 +/- 0.40 mumol/ml, respectively) compared to N (7.99 +/- 0.60 mumol/ml). Phosphatidylcholine was decreased in A (62.64 +/- 2.20% PL) compared to N (76.27 +/- 2.05% PL). Phosphatidylglycerol was 11.58 +/- 1.21% PL in N and was decreased to 6.48 +/- 1.43% PL in A. SP-A was 123.64 +/- 20.66 micrograms/ml in N and was decreased to 49.28 +/- 21.68 micrograms/ml in AR and to 29.88 +/- 8.49 micrograms/ml in A. SP-B was 1.28 +/- 0.33 micrograms/ml in N and was decreased to 0.57 +/- 0.24 micrograms/ml in A. STmin was increased in AR (15.1 +/- 2.53 dyn/cm) and A (29.04 +/- 2.05 dyn/cm) compared to N (7.44 +/- 1.61 dyn/cm). These data demonstrate that the chemical composition and functional activity of surfactant is altered in ARDS. Several of these alterations also occur in AR, suggesting that these abnormalities occur early in the disease process.
急性呼吸窘迫综合征(ARDS)的特征是肺损伤和肺泡II型细胞受损。本研究旨在确定内源性表面活性物质在ARDS中是否发生改变。对有发生ARDS风险的患者(AR组,n = 20)、患有ARDS的患者(A组,n = 66)以及正常受试者(N组,n = 29)进行了支气管肺泡灌洗。对粗制表面活性物质沉淀进行了总磷脂(PL)、单个磷脂、表面活性蛋白A(SP-A)、表面活性蛋白B(SP-B)和最小表面张力(STmin)的分析。与N组(7.99±0.60 μmol/ml)相比,AR组和A组的PL均降低(分别为3.48±0.61和2.47±0.40 μmol/ml)。与N组(76.27±2.05% PL)相比,A组的磷脂酰胆碱降低(62.64±2.20% PL)。N组中磷脂酰甘油为11.58±1.21% PL,在A组中降至6.48±1.43% PL。N组中SP-A为123.64±20.66 μg/ml,在AR组中降至49.28±21.68 μg/ml,在A组中降至29.88±8.49 μg/ml。N组中SP-B为1.28±0.33 μg/ml,在A组中降至0.57±0.24 μg/ml。与N组(7.44±1.61 dyn/cm)相比,AR组(15.1±2.53 dyn/cm)和A组(29.04±2.05 dyn/cm)的STmin升高。这些数据表明,ARDS中表面活性物质的化学成分和功能活性发生了改变。其中一些改变在AR中也会出现,提示这些异常在疾病过程早期就已发生。